Logos Global Management LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Logos Global Management LP reported 46 stock positions worth $854.6 million. Its top holding was Ideaya Biosciences (IDYA) at 9.0% of the portfolio, followed by Janux Therapeutics (JANX, 7.8%) and Revolution Medicines (RVMD, 7.4%). Compared with Q3 2024, it opened 16 new positions, sold out of 23, added to 11 and reduced 9. The biggest buy was a new position in Biontech SE-ADR (BNTX) and the biggest sale Structure Therapeutics (GPCR, shares −44%).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001792126
- Portfolio Value
- $854.6M (Q4 2024)
- SEC Filing
- 0001172661-25-001041 ↗ filed Feb 14, 2025
Holdings Value
Holdings 46 stocks · $854.6M
| IDYA Ideaya Biosciences Inc. | 9.02% | 3,000,000 | $77.1M | Add +42.9% |
| JANX Janux Therapeutics Inc. | 7.83% | 1,250,000 | $66.9M | Add +25.0% |
| RVMD Revolution Medicines Inc. | 7.42% | 1,450,000 | $63.4M | Add +20.8% |
| CYTK Cytokinetics Inc. | 4.95% | 900,000 | $42.3M | Add +125.0% |
| VERA Vera Therapeutics Inc. | 4.33% | 875,000 | $37.0M | Add +75.0% |
| BNTX Biontech SE-ADR | 4.00% | 300,000 | $34.2M | New |
| MRUS Merus NV | 3.69% | 750,000 | $31.5M | Add +30.4% |
| ERAS Erasca Inc. | 3.67% | 12,500,000 | $31.4M | Add +14.7% |
| INSM Insmed Inc. | 3.64% | 450,000 | $31.1M | New |
| OCUL Ocular Therapeutix Inc. | 3.50% | 3,500,000 | $29.9M | No change |
| NBIX Neurocrine Biosciences Inc. | 3.19% | 200,000 | $27.3M | New |
| DSGN Design Therapeutics Inc. | 3.04% | 4,217,627 | $26.0M | No change |
| PCVX Vaxcyte Inc. | 2.87% | 300,000 | $24.6M | No change |
| AKRO Akero Therapeutics Inc. | 2.60% | 800,000 | $22.3M | No change |
| JAZZ Jazz Pharmaceuticals PLC | 2.52% | 175,000 | $21.6M | New |
| GPCR Structure Therapeutics Inc. | 2.22% | 700,000 | $19.0M | Reduce -44.0% |
| OLMA Olema Pharmaceuticals Inc. | 2.19% | 3,208,875 | $18.7M | No change |
| BPMC Blueprint Medicines Corp. | 2.04% | 200,000 | $17.4M | New |
| TVTX Travere Therapeutics Inc. | 2.04% | 1,000,000 | $17.4M | Reduce -9.1% |
| APLS Apellis Pharmaceuticals Inc. | 1.87% | 500,000 | $16.0M | New |
| SLNO Soleno Therapeutics Inc. | 1.84% | 350,000 | $15.7M | New |
| ALKS Alkermes PLC | 1.68% | 500,000 | $14.4M | New |
| APGE Apogee Therapeutics Inc. | 1.59% | 300,000 | $13.6M | New |
| ARVN Arvinas Inc. | 1.57% | 700,000 | $13.4M | Add +75.0% |
| ANNX Annexon Inc. | 1.53% | 2,550,000 | $13.1M | Reduce -1.9% |
| IRON Disc Medicine Inc. | 1.48% | 200,000 | $12.7M | Reduce -78.6% |
| SYRE Spyre Therapeutics Inc. | 1.36% | 500,000 | $11.6M | Add +150.0% |
| EWTX Edgewise Therapeutics Inc. | 1.25% | 400,000 | $10.7M | Reduce -11.1% |
| DYN Dyne Therapeutics Inc. | 1.24% | 450,000 | $10.6M | Add +181.3% |
| PLRX Pliant Therapeutics Inc. | 1.16% | 750,000 | $9.9M | New |
| DRUG Bright Minds Biosciences Inc. | 1.03% | 245,000 | $8.8M | New |
| YMAB Y-Mabs Therapeutics Inc. | 0.92% | 1,000,000 | $7.8M | Add +25.0% |
| IMVT Immunovant Inc. | 0.87% | 300,000 | $7.4M | Reduce -72.7% |
| GERN Geron Corp. | 0.83% | 2,000,000 | $7.1M | New |
| ACRS Aclaris Therapeutics Inc. | 0.64% | 2,222,222 | $5.5M | New |
| TRVI Trevi Therapeutics Inc. | 0.60% | 1,250,000 | $5.2M | Reduce -54.5% |
| ATXS Astria Therapeutics Inc. | 0.52% | 500,000 | $4.5M | No change |
| UNICYCIVE THERAPEUTICS INC | 0.47% | 5,078,927 | $4.0M | No change |
| AEROVATE THERAPEUTICS INC | 0.43% | 1,400,000 | $3.7M | New |
| RAPP Rapport Therapeutics Inc. | 0.43% | 208,910 | $3.7M | No change |
| ATYR Atyr Pharma Inc. | 0.42% | 1,000,000 | $3.6M | Reduce -50.0% |
| ALLK Allakos LLC | 0.41% | 2,900,000 | $3.5M | No change |
| ELVN Enliven Therapeutics Inc. | 0.37% | 140,000 | $3.1M | Reduce -71.7% |
| SEPN Septerna Inc. | 0.36% | 134,202 | $3.1M | New |
| ARTV Artiva Biotherapeutics Inc. | 0.17% | 145,089 | $1.5M | No change |
| GLYCOMIMETICS INC | 0.16% | 5,400,000 | $1.3M | New |
Other holdings (1): bonds, preferreds, convertibles and warrants · $15K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 66,666 | $15K | New |
Total filed on the 13F, all lines: $854.6M.
Portfolio Sells Q3 2024 → Q4 2024
| GPCR Structure Therapeutics Inc. | Reduce -44.0% | 2.22% | −3.92 |
| IRON Disc Medicine Inc. | Reduce -78.6% | 1.48% | −3.66 |
| CLDX Celldex Therapeutics Inc. | Sold out | 0.00% | −3.43 |
| IONS Ionis Pharmaceuticals Inc. | Sold out | 0.00% | −3.37 |
| IMVT Immunovant Inc. | Reduce -72.7% | 0.87% | −2.64 |
| LKFT Lakefront Biotherapeutic-ADR | Sold out | 0.00% | −2.58 |
| COGT Cogent Biosciences Inc. | Sold out | 0.00% | −2.42 |
| BCAX Bicara Therapeutics Inc. | Sold out | 0.00% | −2.28 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −2.10 |
| BEAM Beam Therapeutics Inc. | Sold out | 0.00% | −1.37 |
| BCYC Bicycle Therapeutics PLC-ADR | Sold out | 0.00% | −1.27 |
| ELVN Enliven Therapeutics Inc. | Reduce -71.7% | 0.37% | −1.05 |
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −0.86 |
| CMPS Compass Pathways PLC | Sold out | 0.00% | −0.82 |
| ORKA Oruka Therapeutics Inc. | Sold out | 0.00% | −0.71 |
| RCKT Rocket Pharmaceuticals Inc. | Sold out | 0.00% | −0.67 |
| HELP Cybin Inc. | Sold out | 0.00% | −0.60 |
| ENGN Engene Holdings Inc. | Sold out | 0.00% | −0.59 |
| AVTX Avalo Therapeutics Inc. | Sold out | 0.00% | −0.57 |
| LCTX Lineage Cell Therapeutics Inc. | Sold out | 0.00% | −0.51 |
| TRVI Trevi Therapeutics Inc. | Reduce -54.5% | 0.60% | −0.43 |
| SLN Silence Therapeutics PLC-ADR | Sold out | 0.00% | −0.41 |
| NXTC Nextcure Inc. | Sold out | 0.00% | −0.38 |
| ADVM Adverum Biotechnologies Inc. | Sold out | 0.00% | −0.33 |
| ANNX Annexon Inc. | Reduce -1.9% | 1.53% | −0.19 |
| NMRA Neumora Therapeutics Inc. | Sold out | 0.00% | −0.15 |
| EWTX Edgewise Therapeutics Inc. | Reduce -11.1% | 1.25% | −0.10 |
| IOBTQ Io Biotech Inc. | Sold out | 0.00% | −0.06 |
| SKYE Skye Bioscience Inc. | Sold out | 0.00% | −0.04 |
| BOLD Boundless Bio Inc. | Sold out | 0.00% | −0.02 |
| ATYR Atyr Pharma Inc. | Reduce -50.0% | 0.42% | +0.03 |
| TVTX Travere Therapeutics Inc. | Reduce -9.1% | 2.04% | +0.31 |
Portfolio Buys Q3 2024 → Q4 2024
| BNTX Biontech SE-ADR | New | 4.00% | +4.00 |
| INSM Insmed Inc. | New | 3.64% | +3.64 |
| NBIX Neurocrine Biosciences Inc. | New | 3.19% | +3.19 |
| JANX Janux Therapeutics Inc. | Add +25.0% | 7.83% | +2.74 |
| CYTK Cytokinetics Inc. | Add +125.0% | 4.95% | +2.59 |
| JAZZ Jazz Pharmaceuticals PLC | New | 2.52% | +2.52 |
| BPMC Blueprint Medicines Corp. | New | 2.04% | +2.04 |
| APLS Apellis Pharmaceuticals Inc. | New | 1.87% | +1.87 |
| VERA Vera Therapeutics Inc. | Add +75.0% | 4.33% | +1.85 |
| SLNO Soleno Therapeutics Inc. | New | 1.84% | +1.84 |
| ALKS Alkermes PLC | New | 1.68% | +1.68 |
| APGE Apogee Therapeutics Inc. | New | 1.59% | +1.59 |
| IDYA Ideaya Biosciences Inc. | Add +42.9% | 9.02% | +1.57 |
| RVMD Revolution Medicines Inc. | Add +20.8% | 7.42% | +1.32 |
| PLRX Pliant Therapeutics Inc. | New | 1.16% | +1.16 |
| DRUG Bright Minds Biosciences Inc. | New | 1.03% | +1.03 |
| GERN Geron Corp. | New | 0.83% | +0.83 |
| SYRE Spyre Therapeutics Inc. | Add +150.0% | 1.36% | +0.70 |
| ACRS Aclaris Therapeutics Inc. | New | 0.64% | +0.64 |
| DYN Dyne Therapeutics Inc. | Add +181.3% | 1.24% | +0.60 |
| MRUS Merus NV | Add +30.4% | 3.69% | +0.47 |
| ARVN Arvinas Inc. | Add +75.0% | 1.57% | +0.47 |
| AEROVATE THERAPEUTICS INC | New | 0.43% | +0.43 |
| SEPN Septerna Inc. | New | 0.36% | +0.36 |
| ERAS Erasca Inc. | Add +14.7% | 3.67% | +0.34 |
| GLYCOMIMETICS INC | New | 0.16% | +0.16 |
| YMAB Y-Mabs Therapeutics Inc. | Add +25.0% | 0.92% | −0.26 |
Options Activity Q3 2024 → Q4 2024
| APLS Apellis Pharmaceuticals Inc. | call | Sold out | 1,000,000 | $28.8Mbefore exit |
| FULC Fulcrum Therapeutics Inc. | call | Sold out | 1,500,000 | $5.4Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q3 2024 → Q4 2024
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | New | 66,666 | $15K |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $2.3B | ERAS, ABVX, RVMD, IDYA, BNTX |
| Q1 2026 | 63 | $1.9B | RVMD, ERAS, IDYA, PRAX, CNTA |
| Q4 2025 | 63 | $1.5B | RVMD, PRAX, IDYA, OLMA, CDTX |
| Q3 2025 | 52 | $1.0B | RVMD, IDYA, AKRO, ARVN, OCUL |
| Q2 2025 | 44 | $748.6M | IDYA, AKRO, RVMD, JAZZ, IRON |
| Q1 2025 | 38 | $562.5M | IDYA, RVMD, AKRO, JANX, NUVL |
| Q4 2024 | 46 | $854.6M | IDYA, JANX, RVMD, CYTK, VERA |
| Q3 2024 | 53 | $892.7M | IDYA, GPCR, RVMD, IRON, JANX |
| Q2 2024Amended | 50 | $867.8M | IDYA, ARGX, MRUS, RVMD, GPCR |
| Q1 2024 | 49 | $950.2M | IDYA, IMCR, IMVT, OCUL, SRPT |